Who benefits most from the efficiency advancements though?
Governments seem to benefit most as they effectively determine the margin on testing through regulated pricing. Best example of this being Australian pathology Medicare pricing not changing in 20 years. The company invests in technology to improve efficiency/cost and the public and government mostly reap the rewards. It's a good win for society.
Ann: Half Yearly Report and Accounts, page-37
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SHL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$26.30 |
Change
0.460(1.78%) |
Mkt cap ! $12.63B | |||
| Open | High | Low | Value | Volume |
| $25.97 | $26.47 | $25.95 | $26.16M | 994.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1672 | $26.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $26.32 | 75 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| SHL (ASX) Chart |